Inhibition of vascular endothelial growth factor in the treatment of colorectal cancer.

Published

Journal Article (Review)

Angiogenesis is essential for tumor growth and metastasis and is a promising target in the search for new anti-neoplastic agents. Angiogenesis is a tightly regulated process dependent on the complex interplay between inhibitory and stimulatory angiogenic factors. Vascular endothelial growth factor is one of the best characterized of the pro-angiogenic growth factors, and multiple strategies have been developed to inhibit this pathway. Bevacizumab, a monoclonal antibody developed against vascular endothelial growth factor, has shown initial preclinical and clinical activity. This review will outline the conceptual basis of anti-angiogenic therapy, discuss the critical role of vascular endothelial growth factor, and summarize the available data on the use of bevacizumab in colorectal cancer.

Full Text

Duke Authors

Cited Authors

  • Fernando, NH; Hurwitz, HI

Published Date

  • June 2003

Published In

Volume / Issue

  • 30 / 3 Suppl 6

Start / End Page

  • 39 - 50

Pubmed Central ID

  • 12802794

Electronic International Standard Serial Number (EISSN)

  • 1532-8708

International Standard Serial Number (ISSN)

  • 0093-7754

Digital Object Identifier (DOI)

  • 10.1016/s0093-7754(03)00124-6

Language

  • eng